Basilea Pharmaceutica — BARDA backs latest antibacterial programme
Basilea Pharmaceutica has secured a BARDA contract of up to $159m to advance ceftibuten-ledaborbactam etzadroxil, its recently in-licensed oral,...
230 Views
Basilea Pharmaceutica — Gearing up for the next growth phase
Basilea’s H125 results reflected strong sales traction, with revenues up 36.3% y-o-y to CHF104m, underpinned by 21.7% growth in royalties. A key...
256 Views
Basilea Pharmaceutica — New acquisition bolsters antibacterial franchise
Basilea Pharmaceutica has strengthened its antibacterial pipeline with the acquisition of global rights to the novel, orally administered,...
325 Views
Basilea Pharmaceutica — Advancing into Phase III in mould Infections
Basilea Pharmaceutica has commenced the second Phase III study for fosmanogepix, a key step forward for its novel broad-spectrum antifungal...
203 Views
Basilea Pharmaceutica — Innovation meets execution in anti-infectives
We revisit our investment case for Basilea Pharmaceutica as it is navigating a period of heightened business activity, with the US launch of...
426 Views